StreetInsider.com News Articles

Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference

Fri, 09 Oct 2026 15:23:00 -0400

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan’s 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation, on October 20, 2026.

Chardan 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation

Date: Tuesday, October 20, 2026
Location: Lotte New York Palace, New York, NY
Fireside Chat: Tuesday, October 20, 2026 | 11:00am ET
Webcast Link: https://bit.ly/4yPWgp1

An archived recording of the fireside

Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference

Fri, 09 Oct 2026 15:23:00 -0400

Chardan 10th Annual Healthcare Conference: The Next 10 Years of Disruptive Innovation

Date: Tuesday, October 20, 2026
Location: Lotte New York Palace, New York, NY
Fireside Chat: Tuesday, October 20, 2026 | 11:00am ET
Webcast Link: https://bit.ly/4yPWgp1

An archived recording of the fireside

Armenia grants first-ever approvals for Agenus cancer drug combination

Thu, 08 Oct 2026 07:31:35 -0400

Agenus Inc. (NASDAQ: AGEN) announced that Armenia's Ministry of Health has granted marketing authorizations for Botvymo® (botensilimab) and Evamplix® (balstilimab), each approved for use in combination with the other, marking the first such approvals for either medicine anywhere in the world.

The approvals, effective October 2, 2026, cover adult patients with microsatellite stable (MSS) metastatic colorectal cancer without active liver metastases who have previously received available standard therapies. Each authorization is conditional and valid for one year, renewable based on annual clinical updates provided to Armenian regulators.

Under the approved dosing regimen, Botvymo is administered at 75 mg intravenously every six weeks

Armenia grants first-ever approvals for Agenus cancer drug combination

Thu, 08 Oct 2026 07:31:35 -0400

Under the approved dosing regimen, Botvymo is administered at 75 mg intravenously every six weeks

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Thu, 08 Oct 2026 07:30:00 -0400

Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combination
Armenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance data
Approvals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastases
Agenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory path

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Thu, 08 Oct 2026 07:30:00 -0400

Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combination
Armenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance data
Approvals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastases
Agenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory path

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Sat, 03 Oct 2026 10:50:00 -0400

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit
Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Sat, 03 Oct 2026 10:50:00 -0400

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit
Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer

Form 4 AGENUS INC For: Oct 01 Filed by: Wright Timothy

Fri, 02 Oct 2026 15:25:00 -0400

si-local-file:///var/storage/secattach/20261002/27141713.html

Form 4 AGENUS INC For: Oct 01 Filed by: HARRISON THOMAS L

Fri, 02 Oct 2026 15:22:00 -0400

si-local-file:///var/storage/secattach/20261002/27141696.html

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Fri, 02 Oct 2026 09:00:00 -0400

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

The clinical poster will review the features of long-term survivors of refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) who have been treated with BOT+BAL. A second poster will highlight translational research of BOT+BAL in combination

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Fri, 02 Oct 2026 09:00:00 -0400

Rodman & Renshaw Starts Agenus Inc. (AGEN) at Buy

Mon, 28 Sep 2026 07:02:12 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Agenus Inc. (NASDAQ: AGEN) with a Buy rating and a price target of $19.00.

The analyst comments "We are initiating coverage of Agenus with a BUY rating and $19 price target. Our thesis is anchored to the potential for botensilimab plus balstilimab (BOT+BAL) to establish a new perioperative immunotherapy strategy in high-risk, resectable microsatellite-stable (MSS) colon cancer. Agenus offers a distinct setup from a typical metastatic-oncology program: botensilimab is an Fc-enhanced CTLA-4 antibody that, when paired with PD-1 blockade from balstilimab, has produced unusually deep pathologic responses in an immunotherapy-resistant tumor

Rodman & Renshaw Starts Agenus Inc. (AGEN) at Buy

Mon, 28 Sep 2026 07:02:12 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Agenus Inc. (NASDAQ: AGEN) with a Buy rating and a price target of $19.00.

Rodman & Renshaw Starts Agenus Inc. (AGEN) at Buy

Mon, 28 Sep 2026 07:02:12 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Agenus Inc. (NASDAQ: AGEN) with a Buy rating and a price target of $19.00.

Rodman & Renshaw Starts Agenus Inc. (AGEN) at Buy

Mon, 28 Sep 2026 07:02:12 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Agenus Inc. (NASDAQ: AGEN) with a Buy rating and a price target of $19.00.

Chardan Starts Agenus Inc. (AGEN) at Buy

Fri, 18 Sep 2026 05:02:43 -0400

Chardan analyst Andreas Argyrides initiates coverage on Agenus Inc. (NASDAQ: AGEN) with a Buy rating and a price target of $40.00.

For an analyst ratings summary and ratings history on Agenus Inc. click here. For more ratings news on Agenus Inc. click here.

Shares of Agenus Inc. closed at $7.22 yesterday.

Form 4 AGENUS INC For: Aug 05 Filed by: Marcucci Marco Tullio

Wed, 16 Sep 2026 14:41:00 -0400

si-local-file:///var/storage/secattach/20260916/27069821.html

Form 3 AGENUS INC For: Aug 05 Filed by: Marcucci Marco Tullio

Tue, 15 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260915/27065595.html

Form S-3 AGENUS INC

Fri, 11 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260911/27053419.html

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Thu, 10 Sep 2026 07:30:00 -0400

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

The presentation will feature results from the recurrent ovarian cancer cohort of the large Phase 1b C-800-01 study, including patients with platinum-refractory/resistant disease, with analyses by platinum sensitivity status and long-term three-year overall survival.

Presentation Details:

Abstract Title: Next

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Thu, 10 Sep 2026 07:30:00 -0400

Presentation Details:

Abstract Title: Next

Agenus drug combo shows 33% three-year survival in colorectal cancer

Fri, 28 Aug 2026 10:07:39 -0400

Agenus Inc. (Nasdaq: AGEN) announced the peer-reviewed publication of mature Phase 1b clinical results evaluating the combination of botensilimab (BOT) and balstilimab (BAL) in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.

The study, published in Clinical Cancer Research, analyzed 123 heavily pretreated patients who had received a median of three prior lines of therapy. The combination demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33%. Available later-line standard treatments have reported median overall survival of approximately 10 to 14 months in comparable patient populations.

The confirmed objective response rate was

Agenus drug combo shows 33% three-year survival in colorectal cancer

Fri, 28 Aug 2026 10:07:39 -0400

The confirmed objective response rate was

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01